IA期非小细胞肺癌:楔形切除与立体定向放疗的国家分析
该研究基于美国国家癌症数据库2008至2011年数据,比较cT1N0且肿瘤≤2cm的非小细胞肺癌患者接受楔形切除或立体定向体部放疗的生存结局。共纳入6295例患者,楔形切除组4517例(71.8%),立体定向体部放疗组1778例(28.2%)。楔形切除与更好的总生存相关,倾向性评分匹配及中心层面敏感性分析支持该结论。
要点
- 对于cT1N0且肿瘤≤2cm的NSCLC,楔形切除的5年生存率高于立体定向体部放疗。
- 多因素调整后,楔形切除组5年生存率为49.9%,立体定向体部放疗组为31.0%。
- 更频繁使用立体定向体部放疗的中心,其3年死亡观察/预期比值>1的可能性更高。
核心结论
- 在该 national analysis 中,对于IA期非小细胞肺癌,楔形切除与比立体定向体部放疗更好的生存相关。
研究设计与样本
- 回顾性队列研究,使用美国国家癌症数据库2008至2011年数据,纳入cT1N0且肿瘤≤2cm接受立体定向体部放疗或楔形切除的患者。
- 共纳入6295例患者,其中1778例(28.2%)接受立体定向体部放疗,4517例(71.8%)接受楔形切除。
- 采用Kaplan-Meier法和倾向性评分匹配分析评估总生存,并进行中心层面观察/预期死亡比的敏感性分析。
主要发现
- 未匹配分析中,立体定向体部放疗组5年生存率为30.9%,楔形切除组为55.2%(P < .001)。
- 协变量调整后,立体定向体部放疗组5年生存率为31.0%,楔形切除组为49.9%(P < .001)。
- 两个倾向性评分匹配亚组分析均显示立体定向体部放疗与更差的总生存相关(两者P < .05)。
- 更频繁使用立体定向体部放疗而非手术治疗cT1N0且肿瘤<2cm患者的中心,其3年死亡观察/预期比值>1的可能性更高(P = .034)。
临床怎么用
- 对于cT1N0且肿瘤≤2cm的非小细胞肺癌患者,楔形切除可作为立体定向体部放疗的替代选择,并与更好生存相关。
- 中心层面应关注立体定向体部放疗的使用模式与死亡结局的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Lobectomy is considered optimal therapy for early-stage non-small cell lung cancer, but sublobar wedge resection and stereotactic body radiation therapy are alternative treatments. This study compared outcomes between wedge resection and stereotactic body radiotherapy. METHODS: Overall survival of patients with cT1N0 and tumors ≤2 cm who underwent stereotactic body radiotherapy or wedge resection in the National Cancer Data Base from 2008 to 2011 was assessed via a Kaplan-Meier and propensity score-matched analysis. A center-level sensitivity analysis that used observed/expected mortality ratios was conducted to identify an association between center use of stereotactic body radiotherapy and mortality. RESULTS: Of the 6295 patients included, 1778 (28.2%) underwent stereotactic body radiotherapy, and 4517 (71.8%) underwent wedge resection. Stereotactic body radiotherapy was associated with significantly reduced 5-year survival compared with wedge resection in both unmatched analysis (30.9% vs 55.2%, P < .001) and after adjustment for covariates (31.0% vs 49.9%, P < .001). Stereotactic body radiotherapy also was associated with worse overall survival than wedge resection after 2 subgroup analyses of propensity-matched patients (P < .05 for both). Centers that used stereotactic body radiotherapy more often as opposed to surgery for patients with cT1N0 patients with tumors <2 cm were more likely to have an observed/expected mortality ratio > 1 for 3-year mortality (P = .034). CONCLUSIONS: In this national analysis, wedge resection was associated with better survival for stage IA non-small cell lung cancer than stereotactic body radiotherapy.
引用
- Yerokun BA, Yang CJ, Gulack BC, et al. A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2017. PMID: 28461054. doi:10.1016/j.jtcvs.2017.02.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。